Pelacarsen Targets Lp(a) in Black and Hispanic Americans With Heart Disease
A completed Phase IIIb trial tests whether pelacarsen can safely lower Lp(a) in historically underrepresented cardiovascular disease populations.
Summary
Lipoprotein(a), or Lp(a), is a genetic cardiovascular risk factor that standard therapies like statins cannot meaningfully lower. Pelacarsen is an antisense oligonucleotide designed to suppress Lp(a) production in the liver. This Phase IIIb trial by Novartis specifically enrolled Black/African American and Hispanic Americans — groups with elevated cardiovascular risk who are chronically underrepresented in clinical research. Participants had established atherosclerotic cardiovascular disease (ASCVD) and elevated Lp(a). They received monthly subcutaneous injections of either 80 mg pelacarsen or placebo. The study has completed enrollment and data collection. Results will clarify whether pelacarsen's efficacy and safety profile holds across these demographic groups, and whether racial and ethnic disparities in Lp(a)-driven cardiovascular risk can be meaningfully addressed with targeted therapy.
Detailed Summary
Lipoprotein(a) is an independent, largely genetically determined cardiovascular risk factor that affects roughly 20% of the global population. Elevated Lp(a) is associated with increased risk of heart attack, stroke, aortic valve stenosis, and peripheral artery disease. Unlike LDL cholesterol, Lp(a) is not substantially lowered by statins or most conventional lipid therapies, creating a significant unmet need — particularly for patients who already carry established atherosclerotic cardiovascular disease.
Perlacarsen (TQJ230) is an antisense oligonucleotide that works by inhibiting hepatic production of apolipoprotein(a), the defining protein of the Lp(a) particle. Earlier Phase II data demonstrated it could reduce Lp(a) by up to 80% with monthly subcutaneous dosing. The landmark HORIZON trial is evaluating its cardiovascular outcomes benefit in a broad population, but this Phase IIIb study specifically focuses on two groups historically underrepresented in cardiovascular drug development: Black/African American and Hispanic Americans.
This randomized, double-blind, placebo-controlled trial enrolled US participants from these communities who had both elevated Lp(a) levels and established ASCVD. Participants received pelacarsen 80 mg subcutaneously once monthly or matching placebo, on top of standard-of-care cardiovascular risk management. The trial has been completed under Novartis sponsorship.
The health equity dimension of this study is significant. Black Americans have on average higher Lp(a) levels than white Americans — nearly twice as high in some analyses — yet remain underrepresented in trials testing Lp(a)-targeted therapies. Demonstrating consistent efficacy and a favorable safety profile in these groups is essential before broad clinical adoption.
Results from this trial are awaited. Caveats include that full outcome data are not yet published, and the summary here is based on the registry abstract only. The trial was not powered for hard cardiovascular endpoints, focusing instead on Lp(a) lowering and tolerability.
Key Findings
- Phase IIIb trial specifically enrolled Black/African American and Hispanic patients with elevated Lp(a) and ASCVD — historically underrepresented groups.
- Pelacarsen 80 mg monthly subcutaneous injection targets hepatic apolipoprotein(a) production to reduce Lp(a) levels.
- Black Americans have on average nearly twice the Lp(a) levels of white Americans, making this population especially relevant.
- Trial has completed, though published efficacy and safety results are not yet available in the public domain.
- No standard lipid therapy reliably lowers Lp(a), underscoring the unmet need this drug addresses.
Methodology
Randomized, double-blind, placebo-controlled Phase IIIb trial (NCT06267560) sponsored by Novartis. Participants received pelacarsen 80 mg or placebo subcutaneously once monthly. Endpoints focused on Lp(a) reduction, safety, and tolerability in Black/African American and Hispanic US adults with established ASCVD.
Study Limitations
This summary is based on the ClinicalTrials.gov registry abstract only; full results, effect sizes, and safety data have not been published. The trial was designed to assess Lp(a) lowering and tolerability, not hard cardiovascular endpoints. Generalizability beyond the enrolled US Black/African American and Hispanic populations requires further study.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.